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Abstract 
One major objective for our evolving understanding in the treatment of cancers will be to address how a combina-
tion of diagnosis and treatment strategies can be used to integrate patient and tumor variables with an outcome-
oriented approach. Such an approach, in a multimodal therapy setting, could identify those patients (1) who should 
undergo a defined treatment (personalized therapy) (2) in whom modifications of the multimodal therapy due to 
observed responses might lead to an improvement of the response and/or prognosis (individualized therapy), (3) who 
might not benefit from a particular toxic treatment regimen, and (4) who could be identified early on and thereby 
be spared the morbidity associated with such treatments. These strategies could lead in the direction of precision 
medicine and there is hope of integrating translational molecular data to improve cancer classifications. In order to 
achieve these goals, it is necessary to understand the key issues in different aspects of biotechnology to anticipate 
future directions of personalized and individualized diagnosis and multimodal treatment strategies. Providing an over-
view of translational data in cancers proved to be a challenge as different methods and techniques used to obtain 
molecular data are used and studies are based on different tumor entities with different tumor biology and prognoses 
as well as vastly different therapeutic approaches. The pros and cons of the available methodologies and the potential 
response data in genomics, microRNA, epigenetics and proteomics with a focus on upper gastrointestinal cancers are 
considered herein to allow for an understanding of where these technologies stand with respect to cancer diagnosis, 
prognosis and treatment.
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Introduction
According to the surveillance, epidemiology and end 
results (SEER) database, the estimated incidence for the 
USA of male-predominant upper gastrointestinal (GI) 
cancer (esophagus and gastric) includes 13.6  % of can-
cers of the digestive system and 2.4 % of all cancer sites 
with an observed peak in cancer rates in 1991 followed 
by a decrease of 24 % in men and 16 % in women through 
2009, but esophageal cancer remains the 5th leading 
cause of cancer deaths in males between the ages of 40 
and 59 years [1]. Elsewhere, Iranian colleagues reported 
the high incidence of esophageal cancer as an esopha-
geal cancer belt comparing it with the incidence of laryn-
geal cancer [2]. The high incidences of upper GI cancers 
in northern Iran, Kazakhstan, northern central China, 
(especially Linxian Province), Japan and Singapore [3] 
can be thought of as an upper GI cancer terrestrial belt.
Despite many variables [4] epidemiologic observa-
tions are of value. Since the identification of Helicobacter 
pylori (H. pylori), the incidences in gastric cancers have 
decreased worldwide, but there are reports of increases 
in esophageal squamous cell carcinomas (ESCC) as well 
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as of adenocarcinomas of the esophago-gastral junction 
[5]. On the other hand, there has been a shift of distal gas-
tric carcinomas to the proximal area of subcardial adeno-
carcinoma of the esophago-gastral junction (AEG Type 
III) and cardia localization (AEG Type II) over an 80-year 
period. This shift in tumor localization and its differences 
with rising incidences in the US or Asia are not well 
understood [5, 6] and provides an epidemiological chal-
lenge to identify and explain the worldwide differences 
in order to create effective preventive strategies. Eradi-
cation therapy for H. pylori and/or Barrett’s metaplasia 
alone cannot be the sole explanation as metaplasia of the 
esophago-gastric mucosa results in just 2  % mortality 
within 10 years of diagnosis [7]. Currently, ssurveillance 
seems to be the most important preventive strategy given 
the implementation in Korea and Japan of early tumor 
categories through nationwide screening programs with 
more favourable prognoses and patient outcomes [8]. 
The absence of an aggressive screening program may be 
one explanation of why, in Western countries such as the 
USA, 75  % of patients with upper GI cancers are diag-
nosed with locally advanced tumor categories and with 
correspondingly lower survival rates [5]. It is generally 
accepted that infection with H. pylori results in chronic 
inflammation, gastritis, and peptic ulcer [9]. The effects 
of such chronic inflammation are observed in more than 
60 % of gastric cancer patients [10]. It is of molecular rel-
evance that E-Cadherin can be observed 48  h after H. 
pylori infection in small vesicles [11] and that membrane 
vesicles of bacteria contain lipopolysaccharides, chromo-
somal deoxyribonucleic acid (DNA), plasmids, and phage 
DNA [12].
Studies using irradiated human skin fibroblasts have 
revealed the autocrine function of cyclooxygenase-2 
(=Prostaglandin G/H synthetase 2, =COX-2-) dependent 
prostaglandin (PGE2) and cytokine production in con-
junction with nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κβ-) dependent gene expression 
of cytokines such as Interleukin 1 beta (IL-1B), IL-3, 
IL-6, IL-8, TNF and PTGS2/COX-2 [13]. Therefore, it 
appears that chronic inflammation is one of the impor-
tant sequences in accordance with a recently proposed 
multistep process of carcinogenesis [14, 15].
The importance of inflammation in carcinogenesis 
is supported by findings showing that H. pylori induces 
PTGS2/COX-2 signaling in pre-cancerous lesions and 
that anti-H. plyori treatment results in a decrease of 
PGE2 levels with an observed regression of gastric pre-
cancerous lesions [16]. This also explains why chronic 
inflammation plays a pivotal role early in cancer and 
why, until recently, the origin of less than 15 % of all can-
cers were shown to be hereditary based on the somatic 
mutation theory that has been predominant for some 
85 years [14, 15]. From genetically derived cancers (esti-
mated to account for some 5 to 10 % of all cancers) only 
about 1 % represents gastric carcinomas, 3–5 % for colo-
rectal cancers, and about 8  % for breast cancers (breast 
cancer 1, early onset = BRCA1 or breast cancer 2, early 
onset = BRCA2) [17–19].
Recently, it has been suggested that in order to more 
accurately elucidate the origin of cancers, a detailed per-
sonalized and individualized conceptual model is needed 
in terms of both strategy and content [20]. Both seem 
more difficult than previously assumed as the necessity 
of providing available and missing evidence is required 
to bring about the integration of translational molecular 
biological data to clinical processes such as the cancer 
classifications proposed by the American Joint Cancer 
Committee (AJCC). The speed of progress in molecular 
biology makes such an endeavor difficult and also new 
technologies e.g. complex nanoparticles might will have 
significant influence [21]. One aspect involves evaluat-
ing available knowledge in a critical manner. Herein, we 
review translational data in genomics, microRNA, epi-
genetics and proteomics (Fig.  1) (modified according 
to [22]) for monitoring responses and, where available, 




General The invention of the polymerase chain reaction 
(PCR) in 1955 by Kjell Kleppe and Ian J. Molineux, and its 
subsequent modification by Kary B. Mullis in 1983 helped 
realize its potential and in so doing revolutionized biol-
ogy and medicine [23–25]. PCR allows the amplification 
of genetic information from a few copies or a single piece 
of DNA. Various modifications in enzymes, quenchers, 
primers and protocols are used depending on the specific 
goal of the researcher and the questions to be addressed. 
However, the wide spectrum of modifications carries with 
it the burden of “open-to-interpretation” results and, con-
sequently, their significance or lack thereof. Quantitative 
real-time reverse-transcription polymerase chain reac-
tion (qRT-PCR) has been widely used to identify gene 
expression profiles in various cancers and probe differ-
ences between the genetic makeup of cancer versus nor-
mal tissues [26]. Even though qRT-PCR is perceived as 
less labor-intensive and a more high-throughput method 
than conventional RT-PCR (which involves a cDNA syn-
thesis step) two opportunities for variability include tem-
plate preparation and the dispensing of reagents. Sample 
collection is a crucial step in the evaluation of the gene 
expression profiles between tissues.
Up until recently, tissue RNA extraction was car-
ried out from the entire gross resection and/or biopsy. 
Page 3 of 16Brücher et al. Clin Trans Med  (2016) 5:13 
Typically, these tissues consist of a large number of cells 
with only a small percentage being cells of interest. This 
is particularly important if qRT-PCR is used to deter-
mine small metastases that consist of a small number 
of cells (10–100  cells/site) and consequently stay unde-
tected because of being masked by the expression level 
of surrounding cells. This example reveals that tissue 
sampling is a crucial step in the quality of data obtained 
and in their subsequent interpretation. Tissue sampling 
is performed with needles that collect a predetermined 
volume of the tissue of interest. This method of sample 
collection became more popular with the utilization of 
microdissection of the samples by robots that allowed for 
the collection of small amounts of material (as little as a 
single cell). However, this increase in dissection capabil-
ity was not accompanied by a corresponding increase in 
the capability to perform qRT-PCR. Recently, a single cell 
RNA expression kit became available [27] but its use in 
high-output clinical facilities remains to be evaluated. 
Thus, caution has to be exercised when interpreting qRT-
PCR results.
Results from this approach reflect “one” brief moment 
and only represent the steady state mRNA levels dur-
ing the time the tissue sample was taken. Therefore, 
quantification of mRNA levels yields information that is 
measured during that single time point. No information 
about mRNA integrity and/or protein level is obtained.
The recently described detection of micro RNA 
(=miRNA, miR) introduced yet another complexity to 
the value of qRT-PCR namely post-transcriptional modi-
fication of translation in which mRNA level is stable 
with attenuation of protein synthesis. In addition, there 
is an influence by mRNA silencing and mRNA splitting 
such that qRT-PCR no longer represents being a meas-
ure of functional expression. RT-PCR data provide less 
usable information about protein activity or about pos-
sible mutations that the target gene might harbor unless 
it is in the primer binding region. Primer design can 
partially compensate for the problem of mutations by 
specifically designing primers to target small point muta-
tions and large deletions but that requires knowing the 
sequences of these mutations. Therefore, for complete 
and biologically relevant analysis of gene expression it 
is necessary to complement qRT-PCR information with 
data that derived from immunohistochemistry and bio-
chemical assays. Additionally, the qRT-PCR method 
itself is fraught with issues such as loading of reagents, 
variability between technicians, normalization between 
samples and choice of housekeeping genes. This has been 
reviewed in detail [28, 29].
Fig. 1 Schematic drawing of various types of diagnostic and molecular biological options for science and research (modified according to [22])
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Tumor heterogeneity and  mutations Intra-patient het-
erogeneity is a challenge for developing effective thera-
pies. With progress in the human genome project, initial 
promises such as base pair resolution, genome wide and 
exon sequencing have become routine. Nowadays, the 
use of sequencing allows for the collection of enormous 
amounts of data with the ability to decipher the meaning 
of the data and attempt to translate these into the treat-
ment of cancer patients. However, 99.9 % of all mutations 
that occur within the coding regions of the genome are 
not fully understood nor have they been thoroughly inves-
tigated. Additionally, the number of mutated genes and 
mutations per gene or per cancer in the coding region 
varies greatly [30]: Some 95–97 % of mutations are single-
base substitutions and 3–5  % constitutes insertions and 
deletions. Furthermore, of the reported single-base muta-
tions, some 90.7 % are missense changes, 7.6 % nonsense, 
and 1.7 % involves splice sites that are in non-translated 
regions right after the start or stop codons.
The number of mutated genes varies with smaller num-
ber of somatic mutations observed in the younger patient 
population in comparison with older patients with the 
same cancer. The number of observed mutations also 
varies between tissues hosting the primary cancer. Tis-
sues with high rates of cell division, such as the colon or 
skin, have larger numbers of mutations per cell compared 
to cancers with slowly dividing tissues i.e., brain [30, 31]. 
The enormous variability of the mutations combined 
with the fact that more than 50 % of mutations occur in 
the cell before the cancer phenotype is established intro-
duces a high noise to signal into genome and/or exon 
sequencing that confounds the interpretation of data [30, 
31]. It has been assumed that mutations occur over long 
periods of time, in some cases over several decades and 
this fact alone suggests that sequencing results may vary 
greatly as a function of the time of sample collection.
Furthermore, it was assumed that mutations occurred 
after a long latency period of several decades. It has 
been inferred that this is a main reason for the variabil-
ity in results. Recently it was demonstrated, using tumor 
exome sequencing, that acute lymphoblastic B-cell leuke-
mia (B-cell ALL) is not caused by mutations but rather 
by infection and that mutations of Janus-activated kinase 
3 (JAK-3) occur after carcinogenesis is already underway 
[32]. Thus, somatic mutations are increasingly seen as 
epiphenomena and subsequent events [14, 15].
An apple found in a car is not synonymous with the 
proof that apples grow in cars.
The observation of a mutation within a tissue or 
tumor (i.e., a somatic mutation) is not synonymous 
with proof that mutations are causally related to the 
cancer.
In contrast, a recent report suggested that oncogenes, 
in particular, Kirsten rat sarcoma viral oncogene (KRAS), 
is causally linked to de novo tumor development in 
human mammary cells, in  vitro and when implanted in 
immune-deficient mice [33]. Normal human mammary 
cell types obtained from 37 normal human reduction 
mammoplasty samples included basal cells (BCs), lumi-
nal progenitors (LPs), luminal cells (LCs) and stromal 
cells (SCs). Such cells were exposed to encoding lentiviral 
preparations (encoding complementary DNAs) for TP53 
and TP53-GFP (green fluorescent protein), phosphati-
dylinositol-45-bisphosphate 3-kinase catalytic subunit 
alpha (PIK3CA) and PIK3CA-YFP (yellow fluorescent 
protein), KRAS and mCherry-KRAS, and in some experi-
ments, to a library of biologically neutral, barcoded lenti-
viral GFP vectors to allow subsequent clonal tracking of 
their progeny using a DNA sequencing approach. After-
wards these cells were embedded in a collagen gel and 
the gels transplanted into highly immunodeficient NOD-
SCID or NRG female mice. The results showed that BCs 
and/or LPs isolated from 17 of 27 normal donors and 
exposed to all three oncogenic vectors produced tumors 
resembling invasive ductal carcinomas within 8 weeks at 
similar overall frequencies (46 % of BC isolates and 61 % 
of LP isolates). However, some major questions were not 
addressed such as,
  • What happened in the other 54 % of BC isolates and 
39 % of LP isolates?
  • Why did identical treatment of LCs and SCs isolated 
from three of these samples not produce any tumors 
in the same 8-week period?
Tumors were obtained only when the KRAS oncogene 
was included and even on its own (64/102  =  63  % for 
all transductions that included KRAS) compared with 
1/12 = 8 % when KRAS was not present—does this allow 
for the inference that KRAS is the causal factor in the 
observed tumors in mice? The authors suggest that their 
studies provide new insights into the earliest phases of 
malignant transformation in vivo of cells isolated directly 
from normal human mammary tissue. Five aspects of this 
study are noteworthy:
1. Rapidity and efficiency (though with high variability) 
with which this process can be induced using a single 
transducing oncogene (KRAS).
2. Considerably heterogeneity displayed in the num-
bers, phenotypes and growth behavior of clonally 
tracked human cells with tumorigenic activity in vivo 
within 2–8 weeks.
3. Lack of strong influence of human mammary cell 
type initially transduced with frequency of clones 
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generated, the histopathology of the tumors pro-
duced or their loss of lineage-specific expression 
profiles. This suggests a greater effect of the potent 
transforming role of the KRAS oncogene in these 
cells. What prevents KRAS from being 100 % effec-
tive in this mouse model?
4. Frequent delayed activation of clonal growth 
observed in secondary tumors. This latency could 
either be biologically determined, reflecting an ori-
gin of these late-appearing clones from their normal 
counterparts with similar features, or simply reflec-
tive of a stochastic process, as previously indicated 
for established human breast cancer cell lines pas-
saged in vivo.
5. If mainly basal cells, which have special location 
in  vivo, produce cancers as proposed, why are the 
majority of breast cancers found in the epithelial and 
not in basal cells?
The research by this group provides insights to our 
understanding of the role of genetics in the origin of can-
cers, but an old dogma—the somatic mutation theory—is 
used to explain the results as “important” even though 
the clinical data tell a different story.
A recent report sheds new light on how enzymes may 
continuously promote mutations in cancer after the car-
cinogenesis process has been initiated. High levels of 
the DNA cytosine deaminase APOBEC3B (A3B) found 
in breast cancers are associated with poor survival and 
increased rates of resistance to tamoxifen [34]: A3B 
changes the microenvironment with observed secondary 
increases in mutation rates of cytosine within the estro-
gen receptor positive breast cell line, MCF-7L. Suppres-
sion of A3B in a xenograft model was associated with 
increased responsiveness to tamoxifen. It was suggested 
that an ongoing stimulus such as a virus, for instance, 
may affect an increase of A3B and that this would 
explain why increased mutation rates are found in locally 
advanced breast cancer.
Furthermore, it has been shown that a liver cancer 
sample of 2.5  cm (1  inch) contains more than 100 mil-
lion mutations [35]. The authors showed that this high 
degree of genetic diversity was independent of whether 
the tumor sample was a thin or thick one. This observa-
tion raises the following questions:
  • Do we know what mutations result in a given per-
centage of harm to an organism?
  • If a mutation is observed, do we know when it 
occurred?
  • Does the detection of mutation reveal when it was 
modified and/or repaired, albeit incorrectly or 
incompletely?
  • What is the fate of any given mutation in a living 
organism and how do we know this?
There are other significant biological challenges as well 
as it has been shown that an identical mutation can result 
in different phenotypes [36]. We now also know that 
there is routine processing of mutations within the physi-
ological context of normal growth as an integral part of 
development and evolution [37]. This raises the issue of 
how we can assume that any mutations being measured 
in tissue is necessarily pro-carcinogenic.
Investigating some 17 million single nucleotide variants 
from genomes of 562 tumors, it was shown that differen-
tial DNA repair, and not mutations, is the primary cause 
of large-scale regional mutation rate variations across the 
human genome [38].
By examining some 450 somatic mutations accumu-
lated in non-repetitive genome sequences from the blood 
of a healthy 115-year old woman, the mass of mutations 
observed were harmless mutations suggesting that “the 
finite lifespan of hematopoetic stem cells (HSCs), rather 
than somatic mutation effects, may lead to hematopoietic 
clonal evolution at extreme ages” [39]. Another report 
analyzed 4742 tumor-normal pairs across 21 cancer 
types; the data set consisted out of “3,078,483 somatic 
single nucleotide variations (SSNVs), 77,270 small inser-
tions and deletions (SINDELs) and 29,837 somatic di-, 
tri- or oligonucleotide variations (DNVs, TNVs and 
ONVs, respectively), with an average of 672 per tumour–
normal pair. The mutations included 540,831 missense, 
207,144 synonymous, 46,264 nonsense, 33,637 splice-site, 
and 2,294,935 non-coding mutations” [40]. These authors 
found 145,000 genetic variations per cancer type. Thus, 
it would appear that somatic mutations are likely an epi-
phenomena and/or constitute events that occur after car-
cinogenesis has begun [14, 15, 41, 42], as there are also 
cancers which are not associated with mutations [43, 44].
The importance of these somatic mutation data is 
mechanistic in that these serve to trace metastasis and to 
evaluate entire pathways since proteins with translated 
mutations interact with the other proteins that may or 
may not be mutated. In this regard, the influence of acti-
vated signaling pathways in the cytoskeleton seems to be 
particularly relevant. The metastasis of epithelial tumor 
cells is exemplified by Syndecan-4 as the actin cytoskel-
eton and cell contractility are modified by a second signal 
path (PKC) [45].
Another variable which influences our understand-
ing is that proteins with translated mutations can result 
in interactions with other proteins. For example, point 
mutations occur at a similar rate in cancer and non-can-
cerous cells and larger genetic material rearrangements 
such as translocations and changes in chromosome 
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numbers, occur more frequently in cancer cells than in 
noncancerous cells which support the importance of the 
timing of sampling [46]. Despite these important chal-
lenges of intratumoral, intermetastatic, intrametastatic 
and inter-patient variability, some important findings 
have been obtained by sequencing methods, primarily 
that more than 138 driver mutations identified to date 
can be divided into pathways involved in cell survival, cell 
fate, and genome maintenance [30].
Sequencing Transcriptome sequencing analysis, also 
known as RNA-seq, has been used in cancer research 
for the detection of transcribed mutations and confir-
mation of known and unknown mutations. RNA-seq 
is performed on the isolated total RNA from a tumor 
versus control samples in order to determine the differ-
ences between the two [47]. Research in prostate cancer 
has revealed seven new cancer-specific gene fusions, two 
involving the E26 transformation-specific or E-twenty-six 
transcription factor family (ETS) genes, ETS transloca-
tion variant 1 (ETV1) and ETS related gene (ERG), and 
four involving non-ETS genes such as CDKN1A (p21), cell 
surface glycoprotein encoded by CD9 gene (CD9), and 
IKBKB (IκK-beta) [48]. Using two different technologies 
for confirmation provides important fusion proteins like 
LnCap and VCaP in prostate cancer cell lines followed by 
identification of those proteins in the patient samples [49]. 
The downregulation of protein tyrosine kinase 6 (PTK6) 
in esophageal squamous cell carcinoma (ESCC) has been 
described [50].
Combining these data using bioinformatics might pro-
vide a better understanding of mutations and their role 
in cancer progression and might also provide insight into 
how miRNA functions as post-transcriptional regulators 
of gene expression in cancer progression [51].
MicroRNA
MicroRNA (miR, miRNA) are small (20–24 nucleotides 
long) well-conserved RNA molecules involved in the 
control of translation of mRNA in the cell. miRNAs asso-
ciated with cancers are called oncomirs. Their discovery 
occurred in 1993 by Ambros, Lee and Feinbaum in the 
nematode, Caenorhabditis elegans [52]. Since then, the 
role of miRNAs has been described in several human 
cancers [53]. There are more than 800 identified miRNAs 
[54] and their expression patterns vary in different can-
cers [55]. Altered miRNA expression has been reported 
for hepatocellular carcinoma [56, 57], pancreatic cancer 
[58, 59], breast cancer [60, 61] papillary thyroid cancer 
[62], chronic lymphocytic leukemia [63] and esophageal 
cancer [64–66]. The results, however, showed that up- 
and/or down-regulation of the miRNA of interest is usu-
ally small when comparing cancerous vs. noncancerous 
tissues [64, 67]. miRNAs can play different roles in esoph-
ageal cancer tumorigenesis exhibiting both pro- and 
anti- proliferative roles and are differentially expressed in 
squamous cell carcinoma and in adenocarcinoma, with 
and without Barrett’s metaplasia [68].
miRNAs have been detected in tissues using qRT-PCR 
and in  situ hybridization [69]. In frozen tissue samples, 
509 mature miRNA assay identified several miRNAs 
distinctively expressed in tumor cells when compared 
to corresponding normal tissue, hsa-miR-103/107 com-
plex, in particular, showed a strong correlation between 
low expression and high survival periods [70]. miRNA-21 
has been proven to control proliferation in  vitro and in 
humans [69, 71]. Although it was suggested, that miRNA 
is part of the cancer secretome, miRNA is not a protein 
and therefore cannot be a part of any protein group. 
These molecules end up in serum and in exosomes. The 
term secretome was coined by Tjalsma in 2000 defining 
the secreted proteins in Bacterium subtilis [72] and, in 
2010, Agrawal suggested using this term for ‘the global 
group of proteins secreted into the extracellular space by 
a cell, tissue, organ, or organism [73].
In the serum of patients with squamous cell carcinoma 
vs. patients with benign disease without inflammation, 
researchers detected exosomes that contain miRNA-21 
[74, 75]. Serum samples depleted of exosomes did not 
have PCR detectable levels of this miRNA. MicroRNA-21 
has been detected in the serum of patients with ESCC 
(100 % in one series) and its level in serum was shown to 
be dependent on the presence of the tumor. After resec-
tion, serum levels of microRNA-21 dropped [74, 75]. 
More clinical trials with larger patient populations are 
needed in order to fully explore the significance of micro-
RNA-21 as a marker and predictor of responses to treat-
ment. So far it is not known if free or exosomal miRNA 
has the most value as a biomarker. However, recently the 
potential to discriminate between precursor metaplastic 
Barrett’s mucosa from adenocarcinoma using miRNA 
was reported [76].
Transfection of colon cancer cell lines with miRNA-
21 led to increases in downregulation of programmed 
cell death protein 4 (PDCD4), transforming growth fac-
tor beta receptor 2 levels of beta-catenin, TCF/LEF 
activity, and expressions of c-Myc, Cyclin-D, which are 
increased in cancer stem cells (CSCs) and where these 
are accompanied by an increased sphere-forming ability 
in vitro and tumor formation in SCID mice [77]. In liver 
regeneration, it is shown that miRNA-21 regulates rapid 
translation of G1/S-specific Cyclin D1 (Cyclin D1 and, 
consequently, increases cell proliferation [78]. Micro-
RNA-22 is also interesting from a response-to-ther-
apy perspective. Researchers did not find a correlation 
between levels of miRNA-22 and overall survival but did 
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find a correlation between its levels in tissue and stage of 
the tumor as well as in the tumor’s response to radiation 
therapy. Cancers with higher expression of this particular 
miRNA responded better to radiation therapy than can-
cers with lower expression of miRNA-22 [79].
Despite the promising aspects of miRNAs in can-
cer diagnosis and treatment, there are several obstacles 
for successful implementation of bench findings into 
the clinic. One such obstacle is detection of miRNA. 
Initially, Northern blotting techniques were used for 
miRNA discovery and detection. This method is rela-
tively insensitive to changes in expression of miRNA 
and requires large amounts of starting material (RNA), 
usually obtained from tumor resections. Quantifica-
tion of miRNA is therefore routinely analyzed by RT-
PCR methods such as the modified Invader assay [80] 
and confocal laser-induces fluorescence detection [81], 
oligo-array based techniques [82] and in situ hybridiza-
tion [83, 84]. It is of note that none of these techniques 
have been adequately validated and that their use in lab-
oratory settings is questionable. For example, RT-PCR is 
semi-quantitative and can provide information on differ-
ences between cancers and noncancerous tissues; how-
ever, this technique has drawbacks as discussed below in 
greater detail. Although, miRNA microassays are suit-
able for large-scale screening, they are semi-quantitative 
and lack sensitivity to discriminate between small differ-
ences. In addition, adjustments of the conditions of the 
assay have to be balanced for large number of miRNAs 
which adds to variability in the efficacy of the method. 
Until now, only certain miRNA species have been pre-
liminarily demonstrated as biomarkers in a clinical set-
ting [85–87].
There are several questions to be answered before 
miRNAs can be widely used in the clinic. First, we have 
to fully understand the role of miRNAs and their bio-
logical effects. Usually, miRNA binds to multiple mRNA 
targets [88, 89] and, by such binding, can “label” mRNA 
to be degraded or translated into protein in an attenu-
ated fashion making it extremely difficult to evaluate the 
importance of charges in expression [88, 90]. There are 
efforts underway, using bioinformatics, to model cellular 
responses to changes in level of particular miRNAs but 
with no definite conclusions as of this writing. The situa-
tion is even more complicated when hyper/hypo-methyl-
ation, histone/DNA interactions are included as we have 
even less mechanistic information to be able to evaluate 
the resulting data.
For example, in breast cancer cell lines, after 5  h of 
exposure to a pro-apoptotic dose of LAQ824, a small 
molecule histone deacetylase inhibitor, changes were 
measured in 40  % of the >60 different miRNA species 
expressed in SKBr3 cells with 22 miRNA species shown 
to be down-regulated and five miRNAs up-regulated 
[91]. This is a much higher percentage than the 5  % of 
affected miRNA. What is the significance of this discrep-
ancy between the levels of miRNA and mRNA? How they 
interact with each other is yet to be understood. Rather 
than a target for intervention, certain miRNA species 
may serve as a diagnostic or as a companion diagnostic 
indicator.
Polymorphisms
The investigation of genetic polymorphisms is important 
as two or more different phenotypes may exist within 
the same individual. Biologists investigate certain point 
mutations in the genotype such as single-nucleotide pol-
ymorphisms (SNPs) or variations in homologous DNA 
by restriction fragment length polymorphisms (RFLPs). 
Such investigations are performed by chromatography, 
chromosome cytology, or genetic data. The mechanisms 
and the distribution of different polymorphisms in dif-
ferent genes are not well understood although these are 
believed to be a reason for evolutionary disparity for nat-
ural selection [92].
Independent from its role in understanding biology 
and especially tumor biology, the investigation of poly-
morphisms should not be expected to reveal clinically 
meaningful data anytime soon. The reasons for this may 
be understood by considering the following information:
 1. We do not understand how polymorphisms reflect 
a disease and/or respond to a treatment, or if they 
react in conjunction with polymorphisms of other 
genes.
 2. The number of SNPs, published on 23 July 2013 
in the single nucleotide polymorphism database 
(dbSNP), was 62,676,337 [93].
 3. Polymorphisms need to include data on the genera-
tion time which is approximately 3 years; the human 
genome consists of base pairs (6.4 billion, 6.4 × 109 
base pairs) and it was assumed, that some 192 muta-
tions (6.4 × 30) per cell generation occur. For exam-
ple, within the Y chromosome this rate was esti-
mated to be between 100 and 200 [94].
 4. Humans have 23 paired chromosomes (46 chromo-
somes) and the human genome project revealed that 
humans probably have 21,000 haploid coding genes 
with approximately 3.3 × 109 base pairs [95].
 5. Chromosome 1 alone with its 249,250,621 base pairs 
has some 4,401,091 variations [96].
 6. Mutations occur at an estimated of around 10−6–
10−10 in eukaryotes [97]; this allows for an approxi-
mation for calculating the possible options and/or 
combinations.
 7. The number of pseudogenes is about 13,000 [95].
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 8. A wide variation is reported in transposable (mobile) 
genetic DNA sequences [98, 99]. For example, Alu 
has about 50,000 active copies while LINE-1 (long 
interspersed element 1) has approximately 100 active 
copies per genome.
 9. To the best of our knowledge, mobile genetic ele-
ments, CLASS I DNA transposons as LTRs (long 
terminal transposanable retroposons) and non-LTR 
retrotransposons, as long interspersed elements 
(LINE), short interspersed elements (SINEs) and 
CLASS II DNA transposons account for more than 
40 % of the total genome [100].
 10. We have additional genomic material such as the 
mitochondrial genome, with little understanding 
of how these interact with genetic elements in the 
nucleus.
 11. The mitochondrial genome is separated from the 
nuclear DNA by the nuclear double membrane; 
however, intranuclear genomic rearrangement takes 
place frequently by transmission of mitochondrial 
DNA into the nuclear genome and especially when 
a normal cell has undergone transformation into a 
cancer cell [101].
 12. Additionally, we have coding and non-coding DNA 
(98 % of human genome) as well as pseudogenes [95] 
but are not aware how these interact in any mean-
ingful detail.
Therefore, logically and computationally it seems 
unlikely to think that a needle in this huge haystack 
might be found in the near future that could help in treat-
ing cancers but there is hope that Big Data might make 
a difference when the requirements for Big Data projects 
are addressed [102].
Epigenetics
The main obstacle to sequencing is epigenetic changes 
which appear to be relevant for understanding cancer 
occurrence and progression. Epigenetic alterations are, by 
definition, mitotically and meiotically heritable changes 
in gene expression that are not caused by changes in the 
primary DNA sequence. The epigenetic modifications 
described in the literature generally comprise histone 
variants, post-translational modifications of amino acids 
of histone proteins, and changes in the methylation sta-
tus of cytosine bases (C) in the context of CpG dinucle-
otides within the DNA itself. Methylation of clusters of 
CpG dinucleotides (CpGs–called “CpG-islands”) in the 
promoter region of genes have been associated with her-
itable gene silencing [103]. Detailed information about 
modified residues of one or two histones are available at 
UniProt [104].
A role for epigenetic factors has been shown for several 
cancers including esophageal cancer [105–107]. Meth-
ylation and de-methylation processes are dynamic, and 
efforts to correlate “methylation fingerprint” with stage 
of the disease suggest that there are variations in meth-
ylation that could be potentially relevant and which cor-
relate to the stage of the disease. Each stage undergoes 
unique epigenetic changes at different steps of disease 
progression in esophageal adenocarcinoma, suggesting a 
step-wise loss of multiple protective barriers against CpG 
island hypermethylation.
Hyper- and hypo-methylation have distinct roles in the 
cell making the fingerprinting of cancer cells complex. 
Hypomethylation usually introduces genome instabil-
ity and genetic rearrangements while hypermethylation 
silences various tumor suppressor genes [108]. The aber-
rant hypomethylation occurs at many different loci sug-
gestive of an overall deregulation of methylation control in 
tumorigenesis in esophageal adenocarcinoma. However, 
there is no evidence for correlation of a distinct group of 
tumors with a CpG island methylator phenotype [109]. 
Efforts were made to investigate methylation patterns of 
DNA in the plasma of cancer patients vs. controls such 
as p16 promoter methylation in ESCC [110]. For exam-
ple, the beta-catenin signaling pathway Wnt modulator 
secreted frizzled-related protein 1 (SFRP1) gene is silenced 
by hypermethylation in ESSC [111] and the COX-2 pro-
moter region is silenced in some ESSC cell lines [112].
The Ras-related protein Rab25 gene implicated in 
endocytic recycling of integrins and suppressor of inva-
sion and angiogenesis was significantly downregu-
lated in ESCC tumor specimens. Rab25 correlated with 
decreased overall survival and was also documented in 
ESCC cell lines as compared to pooled normal tissues 
[113]. Demethylation treatment and bisulfite genomic 
sequencing analyses revealed that downregulation of 
Rab25 expression in both ESCC cell lines and clinical 
samples was associated with promoter hypermethylation 
[113]. Further characterization of Rab25 may allow its 
use as a prognostic biomarker for ESCC and a plausible 
target in ESCC treatment.
Despite encouraging data, caution must be taken inter-
preting these results. For example, these studies typically 
utilized PCRs specifically designed to detect hyper- or 
hypo- methylation of the DNA with all the downfalls of 
this method. Also, the origin of the DNA detected by this 
method is uncertain. There is no evidence whether this 
DNA originates from dying “normal” cells or from cancer 
cells or from both.
Alterations in levels of cell-free DNA in plasma or 
serum as well as increases in the overall level of cell-free 
DNA is not restricted to any particular tumor site, type 
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or grade. However, there are larger amounts of cell-free 
DNA in patients with late stage disease and metastasis. 
Some studies show a correlation between resection of the 
cancer with diminished levels of cell-free DNA in sera 
[114]. However, these studies have been conducted on 
small patient populations and require further investiga-
tion to validate their utility [115].
Proteomics
The measurement of proteins in cancerous vs noncancer-
ous tissues termed “cancer profiling” is a promising area 
for both biomarker discovery and growth in applications 
for healthcare. Molecular profiling for different biomark-
ers in a tissue may assist in obtaining more accurate 
diagnosis for a cancer on a personalized basis providing 
better information on anti-cancer treatments since every 
cancer cell appears to have its own pattern of active genes 
and proteins [116–118]. To achieve this, it will be neces-
sary to collect information on which altered gene expres-
sion will result in what kind of final products (proteins) 
such that the results can be used for diagnostic or for 
monitoring the efficacy of therapy.
Advances in mass spectrometry (MS) have made it 
possible for large-scale analysis of the entire proteome 
of a given tissue to enable the identification of proteins 
in general and specific marker proteins expressed in that 
tissue in particular. Multiple platforms and technologies 
have been utilized including MS-based and antibody-
based analyses. Two-dimensional gel electrophoresis 
(2DE) and liquid chromatography (LC) combined with 
tandem mass spectrometry (LC/MS/MS) are commonly 
used as MS-based proteomic approaches. Microarray 
and immunohistochemistry (IHC) are major platforms in 
antibody-based analyses.
To be able to find proteins that are differentially 
expressed in cancerous tissue only, tissue proteomes 
among normal, precancerous, and cancer patients were 
analyzed and compared. These tissue samples were 
obtained via resection and/or biopsies [119–121]. Body 
fluids including serum and plasma might be better 
choices not only for discovery studies but also for evalu-
ation of patient’s response to a therapeutic reagent since 
they can be accessed readily [122, 123]. On the other 
hand, cancer cell lines were developed and analyzed to 
identify proteins differentially expressed in  vitro, which 
provides an easier and faster way to discover and develop 
cancer-specific biomarkers [124, 125].
With respect to the proteomic study of the upper GI 
tract, a 2DE database for healthy human stomach tissue 
was reported in 2002 [126]. The authors analyzed both 
entire homogenate sand soluble fractions of the stom-
ach. Over 600 protein spots were resolved in the 2DE 
separations. In 2010, Paulo and coworkers identified 
134 proteins from normal gastroduodenal fluid using 
2DE combined with LC–MS/MS [127]. Such studies can 
contribute to identifying disease-specific proteins when 
a diseased sample of the same tissue is analyzed. Like-
wise, using high-throughput and large scale proteomics 
technologies for finding upper GI cancer-specific marker 
proteins have been carried out over the past decade. 
Hundreds of proteins have been identified from various 
cancer patients and cell lines [119, 128–130].
A variety of samples from esophageal cancer/esopha-
geal squamous cell carcinoma (ESCC) patients were 
analyzed and compared with normal tissue. With 
2DE combined with MS platform, transglutaminase 3 
(TGM3), heat shock protein 70 (Hsp70), TPM4-ALK 
fusion oncoprotein 2, myosin light polypeptide 6, kera-
tin I and calreticulin were identified as over-expressed 
in tumor tissues [120, 131]. Using antibody-based tech-
nologies, over expression of protein budding uninhibited 
by benzidazoles 1 homolog beta (BubR1), mitotic arrest 
deficient-like 1 (Mad2), NF-kappaB-activating kinase, 
caspase 10, activator protein-1, alpha-actinin 4 (ACTN4), 
67 kDa laminin receptor (67LR), COX-2, p53, secret pro-
tein acidic and rich in cysteine (SPARC), migration-stim-
ulating factor (MSF), and vascular endothelial growth 
factor C (VEGF-C) were shown to be associated with 
ESCC [132–135].
Using an esophageal cancer cell line, proteins over-
expressed included hsp70, peroxiredoxin-5, non-muscle 
myosin light polypeptide 6, keratin 1, annexin A4, kera-
tin 8, tropomyosin 3, stress-induced-phosphoprotein 
1, albumin, hsp70 protein 9B precursor, solute carrier 
family 44 Member 3, heterogeneous nuclear ribonucleo-
protein L (hnRNP L), eukaryotic translation initiation 
factor 4A isoform 2, triosephosphate isomerase1 (TPI), 
peroxiredoxin1 (PRX1), forminotransferase cyclodeami-
nase form (FTCD), fibrinogen gamma-A chain precursor, 
kinesin-like DNA binding protein, lamin A/C, cyclophilin 
A (CypA), and transcription factor MTSG1 [136–138].
Most of the proteins differentially expressed in upper 
GI cancers were identified in ESCC cases. Only two pro-
teins, apoC-I and apoC-III, were found to be elevated in 
the serum of patients with stomach cancer [139]. Serum 
amyloid A (SAA) was found in rat plasma injected with a 
stomach cancer cell line SC-M1 and was shown to be up-
regulated in human stomach cancer [140]. These findings 
reinforce the new understanding that chronic inflamma-
tion is one of the key sequences in carcinogenesis [14, 
15].
Large-scale profiling of cancer targets using a proteom-
ics approach has been recognized and this may be a tool 
for seeking novel markers in the future. Until recently, 
different groups applied very different technologies in the 
mapping of novel upper GI cancer-related proteins and 
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this resulted in a challenge for interpreting the disparate 
results. A number of proteins were identified as over-
expressed in cancers and they may be valuable for future 
diagnosis and prognosis. For example, ACTN4 and 67LR 
were found to be up-regulated from stage I to III ESCC, 
where ACTN4 was associated with advanced tumor stage 
and lymph node metastasis whereas 67LR was correlated 
with an advanced tumor stage [133]. It is suggested that 
both ACTN4 and 67LR may be useful for the classifica-
tion and evaluation of progression of ESCC and serve 
as targets for therapy. The levels of VEGF-C expression 
in gastro-esophageal junction adenocarcinoma were 
also found to be associated with stages of the tumor and 
lymph node metastasis. To this end, VEGF-C may be a 
potential biomarker for diagnosis of lymphatic metasta-
sis and prognosis of survival in cardia carcinoma patients 
[135].
MSF was identified on the surface of human esopha-
geal cancer endothelial cells (HECECs) and its anti-
body showed suppression of migration and adhesion of 
HECECs on a fibronectin matrix first induced by MSF. 
Furthermore, a biodistribution assay demonstrated that 
this antibody specifically homed into the xenograft with 
humanized blood vessels and suppressed tumor growth 
by inhibition of tumor-related angiogenesis. This obser-
vation, if it holds up in  vivo, suggests that MSF may be 
an anti-angiogenic target for treatment of esophageal 
cancer [134]. TGM3 may be also a prognostic biomarker 
and may provide strategies to prevent recurrence of 
ESCC [131]. Excision repair cross complementing group 
1 (ERCC1) may also be of prognostic value in multimodal 
treated upper GI cancer patients [141].
Hsp70 was found to be over-expressed in both cancer 
tissue samples and cultured cancer cells by several dif-
ferent groups [120, 137, 138] making it a more robust 
marker. As a known chaperone, Hsp70 plays a crucial role 
in forming and recycling nucleocytoplasmic transport 
receptors via direct interaction with the nuclear pore 
complex. Consequently, it regulates the transport of pro-
teins between nucleus and cytoplasm. Multiple reports 
revealed its over-expression in esophageal cancers [120, 
137, 138]. Thus, Hsp70 appears to be involved in the pro-
gression of esophageal cancers. Its impaired expression 
combined with the inability to transport macromolecules 
between the nucleus and the cytoplasm, Hsp70 may serve 
as a biomarker for esophageal cancer [137].
Juan and coworkers introduced five human stomach 
cancer cell lines (SC-M1, HONE-1, CC-M1, OECM1, 
GBM 8401) into nude mice separately [140]. After incu-
bation, plasma was collected, analyzed, and compared 
with plasma from control mice injected with phosphate-
buffered saline. In spite of some acute phase proteins 
found in the plasma of all mice bearing cancer cells, SAA 
was found over-expressed only in mice with the stom-
ach cancer cell line, SC-M1 [140]. The authors suggested 
that SAA may be a specific diagnostic marker for patients 
with gastric cancer.
Using any protein with elevated levels as a therapeutic 
target may, in most cases, be a overly optimistic approach 
given the lack of progress in the recent past using such 
approaches. So far, only Her2 inhibition in Her2-type 
breast cancer has a positive effect in a fair proportion but 
not all of these patients. Elevated levels of a protein may 
serve well as a biomarker but it does not automatically 
follow that it will also serve as an adequate therapeutic 
target. The scientific community might put hope over 
outcome in expecting plausible leads for therapeutics to 
emerge without an in-depth understanding of the science 
underpinning the field.
Besides proteins that are up-regulated in esopha-
geal cancers, several down-regulated proteins were also 
identified. These included subunit alpha type-3 of pro-
teasome, calpain small subunit 1, eIF5A-1, S100-A8 
protein, annexin A1, annexin A2, regulatory subunit of 
dehydrogenase 1calpain, glutamate, histone deacetylase 
10 isoform beta, disulfide-isomerase ER-60 precursor, 
beta-tropomyosin (TMbeta), myosin light chain 2 (and 
its isoform), myosin regulatory light chain 2, and peroxy-
redoxin 2 [120, 136–138].
The increase of newly discovered proteins presents 
both a challenge and an opportunity. In particular, the 
expression level of two proteins, periplakin and clusterin, 
were nearly zero in esophageal cancers when compared 
to healthy tissue [142, 143]. These findings were based on 
Western Blot and IHC analyses without any quantifica-
tion data. We may be able to use periplakin and clusterin 
to assess changes in patients with esophageal cancers. 
However, their scientific significance can be assessed only 
when their values in normal tissues are defined. The lev-
els of periplakin were found to have shifted from the cell–
cell boundary of normal esophageal epithelial cells to the 
cytoplasm of epithelial cells in early esophageal cancer, 
then to have disappeared completely in advanced esopha-
geal cancer [142]. This might be encouraging in that peri-
plakin may not only be useful as a diagnostic biomarker 
but also a marker for the staging of this cancer [142].
As reviewed above, many groups have investigated 
different potential biomarkers in upper GI cancers for 
potential use in making an early diagnosis as well as in 
providing information about prognosis of these cancers. 
However, the major challenges for evaluating the clini-
cal significance of any of new biomarkers remain and 
include:
1. The specificity of occurrence of these proteins,
2. The availability for a drug to get access,
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3. Identifying and quantifying a defined usefulness in 
clinical applications, and
4. A standardization of the different multiple diagnostic 
tools as well as its investigated biorepository.
Another challenge is that new findings will require 
more than a few investigations and validation steps 
although several of them have already been verified by 
various immunoassays for their presence and sub-cellu-
lar locations in cancer tissues. These protein candidates 
include ACTN4, 67LR, VEGF_C, BubR1, Mad2, SAA, 
TGM3 and MSF in which both TGM3 and MSF were fur-
ther investigated in relative functional analysis [131–135, 
140]. Beyond the up-regulated proteins, some down-reg-
ulated proteins found in upper GI cancer cells or tissues 
such as annexin A1, keratin 8, annexin A2, and periplakin 
have also been validated [136, 138, 142].
Due to the availability of antibodies and their costs, 
not every new protein marker can be tested, validated, 
or categorized as its biological (tumor) relevance needs 
to be identified first. Another huge challenge for the pos-
sible identification of a protein as a potential biomarker 
via large-scale protein profiling is the single amino acid 
mutation, and/or small insertions and deletions in the 
coding gene. ELISA, western blotting and IHC poten-
tially provide highly specific protein detection but those 
mutations, insertions and/or deletions are not readily 
detected. For this, a large number of antibodies will need 
to be generated, especially to each and every single pos-
sible combination of mutations and even conversion of 
these mutations on 2D or 3D structure and, consequently, 
the epitope structure. However, an antibody approach is 
not ideal to detect and to quantify protein modifications 
and mutations but there is hope that MS might elucidate 
how best to proceed.
Serum and plasma are under investigation as they 
are much easier to collect and more practical in clinical 
applications. The key issue in protein marker discovery 
in serum/plasma using large-scale and high-throughput 
proteomics technologies is that approximately 99  % of 
protein mass in this sample consists of essentially 20 pro-
teins. Nearly all biomarker proteins are present at low 
levels with a ratio roughly at 1:107, i.e. ng/ml of cancer-
related proteins versus mg/ml of physiological levels of 
albumin [144, 145]. Protein separation prior to sample 
analysis is required and widely used but with variable 
levels of contamination or depletion of the protein of 
interest can occur; and thus, downstream analyses can be 
biased. As a result, new biomarker discovery in serum/
plasma in large-scale proteomics profiling has been lim-
ited. Another drawback for use of serum in the search 
for cancer biomarkers is that even though we possess 
information on which protein from a tissue can enter the 
circulation, the half-life of the target protein may not be 
long enough for it to be detected in serum [146]. There 
is virtually no published data to suggest that the half-
life time of one protein is the same in normal vs. cancer 
tissue.
Finding novel biomarkers would be an important step 
for early diagnosis, treatment and prognosis in oncology. 
The Human Proteome Project with large-scale protein 
profiling on novel biomarkers discovery and validation 
may accelerate advancements in human health given in 
2005 that more than 3020 proteins exist in the current 
data base produced by a number of international labora-
tories [147–149]. This number increased up to 10,546 in 
2014 [150] and some 17,000 in 2015 while approximately 
some 15 % of all proteins have weak proteomic evidence 
and/or are still missing [151]. The significance how prot-
eomics may influence our understanding of carcinogen-
esis and its impact on making of clinical decisions will be 
based on more precise strategies, rather than searching 
for a needle in a haystack without first knowing what the 
needle looks like.
Limitations and challenges of reproducibility
The results from in  vitro studies in cell lines present a 
huge challenge in their evaluation and extrapolation to 
human cancers absent the data to make such a leap. Con-
tamination and incorrect interpretations can result in 
snowball effects of erroneous secondary research [152]. 
The HeLa cell line, cultivated in 1951, from Henrietta 
Lacks, a young cervical cancer patient, is most commonly 
used [153]. Although HeLa is a robust cell line and has 
been used in more than 70,000 studies worldwide, it has 
been known for almost 50 years that approximately 20 % 
of HeLa cell lines are contaminated and such contami-
nation could impact study results [154]. Thus, the top 
four cell line repositories in the US, Germany, and Japan 
should be validated in a standardized manner [155].
The TS gene expression has been under investigation 
in 25 different human ESCC cell lines, 13 from the Japa-
nese Cancer Research Resources Bank and 12 from the 
Leibnitz Institute (DSMZ) German Collection of Micro-
organisms and Cell Cultures [156]. The IC50, a parameter 
used to determine how much of a substance is needed 
to inhibit a biological process by 50 %, ranged from 1 to 
39.8 µmol/L. This finding by Ando et al. is important as 
it unequivocally shows that it is not enough to use a cell 
line for a study given that the range of IC50 s in 25 ESCC 
cell lines under investigation is quite variable. In keep-
ing with this finding is more recent research comparing 
molecular details of cell lines to real tumors by genomic 
profiling [157]. These authors show that common cell 
lines used for research on ovarian cancer do often not 
reflect real tumor biology in humans. This means that the 
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results found in cell lines, more often than not, are not 
representative of the real tumor biology seen in patients.
Furthermore, science faces another challenge which is 
that a lack of reproducibility of existing cancer research is 
recognized and frequently discussed. However, we need 
to remind ourselves that less than 20 % of highly ranked 
so-called “landmark” publications have been shown to be 
irreproducible although these are among the most cited 
references [158]. A recently launched initiative requires 
that authors provide their raw data for a validation check 
[159]. This, together with proposed guidelines, could be 
of helpful to be incorporated into a plan of action thus 
increasing the value and reliability of cancer research. 
There is hope overcoming the issues of contamination 
and poor reproducibility by an U.S. and European ini-
tiative, which is on its way replacing its cell lines with 
patient-derived xenografts (PDX).
Conclusions
There is hope of integrating translational molecular data 
from genomics, microRNA, epigenetics, and proteom-
ics to improve cancer diagnosis, therapy, and facilitate 
cancer classifications. Reviewing the available literature 
for relevance to cancer diagnosis or monitoring of treat-
ment is presently difficult as clearly defined inclusion 
and exclusion criteria in [1] clinical trials as well as [2] 
in molecular research are largely absent. Different tumor 
entities with different tumor biologies, prognoses, and 
different therapeutic approaches make it difficult to make 
informed recommendations. As pointed out, many hith-
erto undervalued criteria such as epidemiology, embryol-
ogy, and molecular biology will be important to consider 
when designing future research and clinical trials [4].
In order to achieve these goals, it is necessary to under-
stand the key issues in different aspects of biotechnol-
ogy so as to anticipate future directions of personalized 
and individualized diagnosis and multimodal treatment 
strategies. Providing an overview of translational data 
in cancers proved to be a challenge as different methods 
and techniques used to obtain molecular data are based 
on different tumor entities with different tumor biol-
ogy and prognoses as well as vastly different therapeutic 
approaches. The pros and cons of the available meth-
odologies and the potential response data in genomics, 
microRNA, epigenetics and proteomics as well as their 
limitations in gastrointestinal cancers are considered to 
allow for an understanding of where these technologies 
stand with respect to cancer diagnosis, prognosis and 
treatment.
A step towards a solution would be if organizations 
dealing with GI cancers create a framework for biological 
studies and for clinical trials dealing with tumor entities. 
This, together with integrating other variables such as 
providing raw data with a validation check would be 
helpful. The replacement of cell lines by patient-derived 
xenografts (PDX) for in  vitro studies may significantly 
enhance the value and rigor of basic and translational 
research.
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